RIM
MYGN icon

RS Investment Management’s Myriad Genetics MYGN Stock Holding History

RS Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,178,740
Closed -$81.5M – 399
2016
Q1 		$81.5M Buy
2,178,740
+179,830
+9% +$6.78M 0.81% 26
2015
Q4 		$86.3M Buy
+1,998,910
New +$84.4M 0.77% 29

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RS Investment Management's MYGN Position: Q2 2016 in Review

RS Investment Management sold out of Myriad Genetics (MYGN) in Q2 2016, closing a stake of 2,178,740 shares — an estimated $81.5M sold.

RS Investment Management first reported a position in MYGN in Q4 2015 and held it in 2 quarters. The position peaked at $86.3M in Q4 2015. 253 funds tracked by Wall St. Rank hold MYGN as of Q2 2016.

  • RS Investment Management reported no remaining Myriad Genetics position as of Q2 2016 after selling out during the quarter.
  • RS Investment Management sold 2,178,740 Myriad Genetics shares in Q2 2016, an estimated $81.5M.
  • RS Investment Management first reported a position in Myriad Genetics in Q4 2015 and held it in 2 quarters.
  • RS Investment Management's Myriad Genetics position peaked at $86.3M in Q4 2015.
  • 253 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.